CD160
Summary: CD160 is an 27 kDa glycoprotein which was initially identified with the monoclonal antibody BY55. Its expression is tightly associated with peripheral blood NK cells and CD8 T lymphocytes with cytolytic effector activity. The cDNA sequence of CD160 predicts a cysteine-rich, glycosylphosphatidylinositol-anchored protein of 181 amino acids with a single Ig-like domain weakly homologous to KIR2DL4 molecule. CD160 is expressed at the cell surface as a tightly disulfide-linked multimer. RNA blot analysis revealed CD160 mRNAs of 1.5 and 1.6 kb whose expression was highly restricted to circulating NK and T cells, spleen and small intestine. Within NK cells CD160 is expressed by CD56dimCD16+ cells whereas among circulating T cells its expression is mainly restricted to TCRgd bearing cells and to TCRab+CD8brightCD95+CD56+CD28-CD27-cells. In tissues, CD160 is expressed on all intestinal intraepithelial lymphocytes. CD160 shows a broad specificity for binding to both classical and nonclassical MHC class I molecules. [provided by RefSeq, Jul 2008].
| Name | OMIM ID | Ensembl ID | HGNC ID | PHARMGKB ID | Map Location |
|---|---|---|---|---|---|
| CD160 molecule | MIM:604463 | Ensembl:ENSG00000117281 | HGNC:HGNC:17013 | PA134943137 | 1q21.1 |
Gene Categories:
DRUGGABLE GENOMEGO terms in CD160
| Term Type | Evidence Type | GO Term ID | GO Des. |
|---|---|---|---|
| MF | IDA | GO:0005102 | signaling receptor binding |
| MF | IPI | GO:0005515 | protein binding |
| MF | IDA | GO:0032393 | MHC class I receptor activity |
| MF | TAS | GO:0038023 | signaling receptor activity |
| CC | TAS | GO:0005886 | plasma membrane |
| CC | IBA | GO:0046658 | anchored component of plasma membrane |
| CC | IDA | GO:0046658 | anchored component of plasma membrane |
| BP | TAS | GO:0006968 | cellular defense response |
| BP | TAS | GO:0007166 | cell surface receptor signaling pathway |
| BP | TAS | GO:0008283 | cell proliferation |
| BP | TAS | GO:0050776 | regulation of immune response |
| BP | IEA | GO:0050829 | defense response to Gram-negative bacterium |
Gene expression in normal tissue: CD160
Gene-model tissue-cancer distribution: Bubble Plot
Gene-drug pathway distribution
Pathways in CD160
| Database | Pathway ID | Pathway Des. |
|---|---|---|
| reactome | R-HSA-1280218 | Adaptive Immune System |
| reactome | R-HSA-168256 | Immune System |
| reactome | R-HSA-198933 | Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell |
Gene-Drug: Aster Plot
| Drug ID | Drug Name | Model Num. |
|---|---|---|
| iGMDRD150 | RITA | 3 |
| iGMDRD560 | MK-2206 | 3 |
| iGMDRD79 | Gemcitabine | 6 |
| iGMDRD415 | LE-135 | 3 |
| iGMDRD121 | GMX1778 | 3 |
| iGMDRD158 | NSC141540 | 6 |
| iGMDRD1008 | SR-II-138A | 3 |
| iGMDRD512 | nutlin 3 | 4 |
| iGMDRD177 | Teniposide | 6 |
| iGMDRD64 | Parbendazole | 3 |
| iGMDRD123 | Isoevodiamine | 4 |
| iGMDRD322 | FK 866 | 2 |
| iGMDRD193 | Fqi1 | 3 |
| iGMDRD237 | ABT-751 | 1 |
| iGMDRD329 | Merck60 | 2 |
Gene in drug-gene network: Network Plot
Gene-drug targets distribution
Gene Structure: PDB
Models in CD160
Copyright © 2018 Modellab | All Rights Reserved
Disclaimer: iGMDR is intended for research purposes only. Its information cannot be used for emergencies or medical or professional advice.